Literature DB >> 24516733

The role of the Epstein-Barr virus in the pathogenesis of some autoimmune disorders - Similarities and differences.

G Füst1.   

Abstract

After a brief summary on the properties of the Epstein-Barr virus (EBV), the course and latency stages of the infection, the characteristics of infectious mononucleosis (IM), and other disorders caused by this virus, as well as the course of the serological responses to EBV, the current paper focuses on the role of EBV in two autoimmune disorders: multiple sclerosis (MS), and systemic lupus erythematosus (SLE). Diverse evidence suggests that infection by EBV during late childhood or young adulthood may have a role in the pathogenesis of MS. These include the similarity between the geographical distribution of IMand MS, the high risk of contracting MS by individuals who have recovered from IM, the elevation of the titers of IgG antibodies against EBV nuclear antigens occurring years before the initial manifestations of MS, and the extremely rare occurrence of MS in individuals seronegative for EBV. However, the data on the mechanism underlying the relationship between EBV and MS are controversial. Moreover, many observations indicate that EBV contributes also to the pathomechanism of SLE. However, this contribution differs from the relationship between EBV and MS, as shown by the lack of any increase in the risk of SLE after IM. In SLE, EBV serology is quantitatively and qualitatively different from the normal response - that is, EBV viral load is higher and a strong cross-reaction can be detected between certain EBV antigens and autoantigens of pathological importance. These observations, along with the findings pointing to a possible role of EBV in rheumatoid arthritis and myasthenia gravis indicate that infection by EBV may be one of the environmental factors, which can facilitate the development of some autoimmune disorders in genetically susceptible individuals.

Entities:  

Keywords:  EBV; SLE; infectious mononucleosis; multiple sclerosis

Year:  2011        PMID: 24516733      PMCID: PMC3918129          DOI: 10.1556/EuJMI.1.2011.4.2

Source DB:  PubMed          Journal:  Eur J Microbiol Immunol (Bp)        ISSN: 2062-509X


  82 in total

1.  MULTIPLE SCLEROSIS AND POLIOMYELITIS.

Authors:  D C POSKANZER; K SCHAPIRA; H MILLER
Journal:  Lancet       Date:  1963-11-02       Impact factor: 79.321

2.  Prevalence of Epstein-Barr virus in Japan: trends and future prediction.

Authors:  Kengo Takeuchi; Keiko Tanaka-Taya; Yukumasa Kazuyama; Yoichi M Ito; Shuji Hashimoto; Masashi Fukayama; Shigeo Mori
Journal:  Pathol Int       Date:  2006-03       Impact factor: 2.534

3.  Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.

Authors:  Michel Moutschen; Philippe Léonard; Etienne M Sokal; Françoise Smets; Michèle Haumont; Pasqualina Mazzu; Alex Bollen; Francoise Denamur; Pascal Peeters; Gary Dubin; Martine Denis
Journal:  Vaccine       Date:  2007-04-18       Impact factor: 3.641

Review 4.  Epstein-barr virus infection and multiple sclerosis: a review.

Authors:  Alberto Ascherio; Kassandra L Munger
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-06       Impact factor: 4.147

Review 5.  Epigenetic dysregulation of epstein-barr virus latency and development of autoimmune disease.

Authors:  Hans Helmut Niller; Hans Wolf; Eva Ay; Janos Minarovits
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

6.  Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis.

Authors:  Jan D Lünemann; Mar Tintoré; Brady Messmer; Till Strowig; Alex Rovira; Héctor Perkal; Estrella Caballero; Christian Münz; Xavier Montalban; Manuel Comabella
Journal:  Ann Neurol       Date:  2010-02       Impact factor: 10.422

Review 7.  The curiously suspicious: a role for Epstein-Barr virus in lupus.

Authors:  J B Harley; I T W Harley; J M Guthridge; J A James
Journal:  Lupus       Date:  2006       Impact factor: 2.911

8.  Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.

Authors:  Tatjana Klatt; Qin Ouyang; Thomas Flad; Ina Koetter; Hans-Jörg Bühring; Hubert Kalbacher; Graham Pawelec; Claudia A Müller
Journal:  J Rheumatol       Date:  2005-02       Impact factor: 4.666

9.  Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.

Authors:  Mattias Magnusson; Mikael Brisslert; Kiandoht Zendjanchi; Magnus Lindh; Maria I Bokarewa
Journal:  Rheumatology (Oxford)       Date:  2010-06-14       Impact factor: 7.580

10.  Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood.

Authors:  Uk Yeol Moon; Su Jin Park; Sang Taek Oh; Wan-Uk Kim; Sung-Hwan Park; Sang-Heon Lee; Chul-Soo Cho; Ho-Youn Kim; Won-Keun Lee; Suk Kyeong Lee
Journal:  Arthritis Res Ther       Date:  2004-05-07       Impact factor: 5.156

View more
  4 in total

1.  Serum concentration of immunoglobulin G-type antibodies against the whole Epstein-Barr nuclear antigen 1 and its aa35-58 or aa398-404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis.

Authors:  D Csuka; D Simon; R Hóbor; K Uray; Z Prohászka; Z Bánlaki; P K Jani; Á Szilágyi; F Hudecz; K Rajczy; G Beke; A Boros Major; A Tordai; Z Illés; T Berki; L Czirják; G Füst
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

Review 2.  Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus.

Authors:  Brendan M Giles; Susan A Boackle
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

Review 3.  Infection Elicited Autoimmunity and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An Explanatory Model.

Authors:  Jonas Blomberg; Carl-Gerhard Gottfries; Amal Elfaitouri; Muhammad Rizwan; Anders Rosén
Journal:  Front Immunol       Date:  2018-02-15       Impact factor: 7.561

Review 4.  Multiple sclerosis and myelin basic protein: insights into protein disorder and disease.

Authors:  Vebjørn Martinsen; Petri Kursula
Journal:  Amino Acids       Date:  2021-12-10       Impact factor: 3.520

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.